1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

31 Jul 2020
Admin
News Article

Novartis Receives European Approval For Piqray In Combo With Fulvestrant To Treat Hr+/Her2 Locally Advanced Or Metastatic Breast Cancer With Pik3Ca Mu

Novartis Announced The European Commission (Ec) Has Approved Piqray (Alpelisib) In Combination With Fulvestrant For The Treatment Of Postmenopausal Women, And Men, With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor-2 Negative (Hr+/Her2-) Locally Advanced Or Metastatic Breast Cancer With A Pik3Ca Mutation After Disease Progression Following Endocrine Therapy As Monotherapy. Piqray Is The First And Only Treatment Specifically Approved For People With Advanced Breast Cancer Whose Tumors Harbor A Pik3Ca Mutation, Which Stimulates Tumor Growth And Is Associated With Poor Response To Therapy.&Ldquo;Piqray Is An Important New Therapy For Hr+/Her2- Advanced Breast Cancer Patients Whose Tumors Have A Pik3Ca Mutation, And We Look Forward To Making It Available In Countries Across Europe,&Rdquo; Said Kees Roks, Head Region Europe, And Novartis Oncology. &Ldquo;Knowledge Of Pik3Ca Status Can Better Equip Doctors As They Develop A Personalized Upfront Treatment Plan For Patients. Piqray Offers New Hope For Advanced Breast Cancer Patients With A Pik3Ca Mutation, Who Typically Face A Worse Overall Prognosis.&Rdquo;This Approval Follows A Positive Opinion Granted In May By The Committee For Medicinal Products For Human Use (Chmp) Of The European Medicines Agency (Ema) Based On The Phase Iii Solar-1 Trial Showing That Piqray Nearly Doubled Median Progression-Free Survival (Pfs) Compared To Fulvestrant Alone. Overall Response Rate, An Indicator Of The Proportion Of Patients Who Experience At Least A 30% Reduction In Overall Tumor Size (In Patients With Measurable Disease), Was More Than Doubled When Piqray Was Added To Fulvestrant Compared To Fulvestrant Alone.Patients With Hr+/Her2- Advanced Breast Cancer Should Be Selected For Treatment With Piqray Based On The Presence Of A Pik3Ca Mutation In Tumor Or Plasma Specimens, Using A Validated Test. If A Mutation Is Not Detected In A Plasma Specimen, Tumor Tissue Should Be Tested If Available.Piqray Is A Kinase Inhibitor Developed For Use In Combination With Fulvestrant For The Treatment Of Postmenopausal Women, And Men, With Hr+/Her2-, Pik3Ca-Mutated, Advanced Or Metastatic Breast Cancer Following Progression On Or After Endocrine-Based Regimen. Piqray Is Approved In 48 Countries, Including The Us And European Member States

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!